Biocoat Acquires Chempilots To Expand Its Biomaterial Platform

Company

Location

About

This platform enables the Company to work with its customers across a wide range of interventional products and medical device segments, including neurovascular, ophthalmology, cardiovascular and other interventional specialties. Since its inception, GTCR has invested more than $24 billion in over 270 companies, and the firm currently manages over $27 billion in equity capital. Over the past 31 years, Biocoat has developed a diverse base of both blue-chip and emerging medical device customers, a highly experienced team of engineers and scientists, and state-of-the-art manufacturing and R&D facilities. "We look forward to investing in the business, further building out its scale and capabilities and becoming an increasingly valuable partner to our growing base of customers.""Biocoat has an excellent track record of developing high-quality biocompatible medical coatings formulations using innovative technologies, and we look forward to investing additional capital to support both organic initiatives and strategic follow-on acquisitions in the medical coatings and broader biomaterials sector," said GTCR Managing Director Luke Marker. Founded in 1991 and headquartered in Horsham, Pennsylvania, Biocoat is a leading medical device contract manufacturing organization ("CMO"), specializing in custom, biocompatible hydrophilic coatings for interventional medical devices. About BiocoatFounded in 1991, Biocoat is a leading provider of medical coatings products and services for medical devices in the fast-growing interventional sector.